Considering the global burden of disease associated with IgA nephropathy, it is striking how little data are available about effective therapies for patients. Originally, IgA was seen as a benign entity and the mesangial deposits of IgA that characterize the disease were considered an immunological curiosity. But extended clinical observation confirmed that nearly 30% of affected patients will progress to end-stage kidney disease over 20 to 25 years of follow-up. Immunoglobulin A nephropathy initially requires a genetic predisposition toward the synthesis of IgA 1 molecules with deficient galactosylation of the hinge region of the antibody. This triggers production of autoantibodies, formation of immune complexes, deposition in the glomerular mesangium, and initiation of inflammation.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Trachtman H. Tonsillectomy for the Management of Immunoglobulin A Nephropathy. JAMA Netw Open. 2019;2(5):e194755. doi:10.1001/jamanetworkopen.2019.4755
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: